FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313892806> ?p ?o ?g. }

• W4313892806 endingPage "2190" @default.
• W4313892806 startingPage "2181" @default.
• W4313892806 abstract "PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is not well studied in the neoadjuvant space. METHODS This is a phase II open-label, single-center trial of localized unresectable or high-risk resectable MSI-H/dMMR tumors. Treatment is pembrolizumab 200 mg once every 3 weeks for 6 months followed by surgical resection with an option to continue therapy for 1 year followed by observation. To continue on study, patients are required to have radiographic or clinical benefit. The coprimary end points are safety and pathologic complete response. Key secondary end points are response rate and organ-sparing at one year for patients who declined surgery. Exploratory analyses include interrogation of the tumor immune microenvironment using imaging mass cytometry. RESULTS A total of 35 patients were enrolled, including 27 patients with colorectal cancer and eight patients with noncolorectal cancer. Among 33 evaluable patients, best overall response rate was 82%. Among 17 (49%) patients who underwent surgery, the pathologic complete response rate was 65%. Ten patients elected to receive one year of pembrolizumab followed by surveillance without surgical resection (median follow-up of 23 weeks [range, 0-54 weeks]). An additional eight did not undergo surgical resection and received less than 1 year of pembrolizumab. During the study course of the trial and subsequent follow-up, progression events were seen in six patients (four of whom underwent salvage surgery). There were no new safety signals. Spatial immune profiling with imaging mass cytometry noted a significantly closer proximity between granulocytic cells and cytotoxic T cells in patients with progressive events compared with those without progression. CONCLUSION Neoadjuvant pembrolizumab in dMMR/MSI-H cancers is safe and resulted in high rates of pathologic, radiographic, and endoscopic response, which has implications for organ-sparing strategies." @default.
• W4313892806 created "2023-01-10" @default.
• W4313892806 creator A5003399621 @default.
• W4313892806 creator A5003827387 @default.
• W4313892806 creator A5006024930 @default.
• W4313892806 creator A5006348751 @default.
• W4313892806 creator A5008633199 @default.
• W4313892806 creator A5010261217 @default.
• W4313892806 creator A5010363210 @default.
• W4313892806 creator A5010444343 @default.
• W4313892806 creator A5016574266 @default.
• W4313892806 creator A5019273888 @default.
• W4313892806 creator A5024146796 @default.
• W4313892806 creator A5032970786 @default.
• W4313892806 creator A5037491681 @default.
• W4313892806 creator A5048843293 @default.
• W4313892806 creator A5057123483 @default.
• W4313892806 creator A5057373704 @default.
• W4313892806 creator A5058548448 @default.
• W4313892806 creator A5062181429 @default.
• W4313892806 creator A5063389336 @default.
• W4313892806 creator A5087569453 @default.
• W4313892806 creator A5087623015 @default.
• W4313892806 creator A5088195904 @default.
• W4313892806 creator A5088821817 @default.
• W4313892806 creator A5089703059 @default.
• W4313892806 creator A5090232818 @default.
• W4313892806 date "2023-04-20" @default.
• W4313892806 modified "2023-10-17" @default.
• W4313892806 title "Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors" @default.
• W4313892806 cites W1687191618 @default.
• W4313892806 cites W1841628176 @default.
• W4313892806 cites W1917937632 @default.
• W4313892806 cites W1940241680 @default.
• W4313892806 cites W2044200030 @default.
• W4313892806 cites W2045044035 @default.
• W4313892806 cites W2108006106 @default.
• W4313892806 cites W2127951115 @default.
• W4313892806 cites W2130544215 @default.
• W4313892806 cites W2416227596 @default.
• W4313892806 cites W2622499649 @default.
• W4313892806 cites W2739132742 @default.
• W4313892806 cites W2770647635 @default.
• W4313892806 cites W2805710293 @default.
• W4313892806 cites W2805787234 @default.
• W4313892806 cites W2809278331 @default.
• W4313892806 cites W2894584497 @default.
• W4313892806 cites W2899666133 @default.
• W4313892806 cites W2901973709 @default.
• W4313892806 cites W2983284890 @default.
• W4313892806 cites W2984359187 @default.
• W4313892806 cites W2990310466 @default.
• W4313892806 cites W2991099989 @default.
• W4313892806 cites W3003310139 @default.
• W4313892806 cites W3009786850 @default.
• W4313892806 cites W3015035400 @default.
• W4313892806 cites W3015633913 @default.
• W4313892806 cites W3040650012 @default.
• W4313892806 cites W3047106569 @default.
• W4313892806 cites W3110528877 @default.
• W4313892806 cites W3209367162 @default.
• W4313892806 cites W4200323001 @default.
• W4313892806 cites W4226440498 @default.
• W4313892806 cites W4281732693 @default.
• W4313892806 cites W4283512735 @default.
• W4313892806 cites W4291802844 @default.
• W4313892806 doi "https://doi.org/10.1200/jco.22.01351" @default.
• W4313892806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36623241" @default.
• W4313892806 hasPublicationYear "2023" @default.
• W4313892806 type Work @default.
• W4313892806 citedByCount "30" @default.
• W4313892806 countsByYear W43138928062023 @default.
• W4313892806 crossrefType "journal-article" @default.
• W4313892806 hasAuthorship W4313892806A5003399621 @default.
• W4313892806 hasAuthorship W4313892806A5003827387 @default.
• W4313892806 hasAuthorship W4313892806A5006024930 @default.
• W4313892806 hasAuthorship W4313892806A5006348751 @default.
• W4313892806 hasAuthorship W4313892806A5008633199 @default.
• W4313892806 hasAuthorship W4313892806A5010261217 @default.
• W4313892806 hasAuthorship W4313892806A5010363210 @default.
• W4313892806 hasAuthorship W4313892806A5010444343 @default.
• W4313892806 hasAuthorship W4313892806A5016574266 @default.
• W4313892806 hasAuthorship W4313892806A5019273888 @default.
• W4313892806 hasAuthorship W4313892806A5024146796 @default.
• W4313892806 hasAuthorship W4313892806A5032970786 @default.
• W4313892806 hasAuthorship W4313892806A5037491681 @default.
• W4313892806 hasAuthorship W4313892806A5048843293 @default.
• W4313892806 hasAuthorship W4313892806A5057123483 @default.
• W4313892806 hasAuthorship W4313892806A5057373704 @default.
• W4313892806 hasAuthorship W4313892806A5058548448 @default.
• W4313892806 hasAuthorship W4313892806A5062181429 @default.
• W4313892806 hasAuthorship W4313892806A5063389336 @default.
• W4313892806 hasAuthorship W4313892806A5087569453 @default.
• W4313892806 hasAuthorship W4313892806A5087623015 @default.
• W4313892806 hasAuthorship W4313892806A5088195904 @default.
• W4313892806 hasAuthorship W4313892806A5088821817 @default.
• W4313892806 hasAuthorship W4313892806A5089703059 @default.
• W4313892806 hasAuthorship W4313892806A5090232818 @default.

• next